NASDAQ: TVTX
Travere Therapeutics Inc Stock Ownership - Who owns Travere Therapeutics?

Insider buying vs selling

Have Travere Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Eric M. DubeCEO2026-10-1543,735$26.88
$1.18MBuy
Eric M. DubeCEO2026-10-1578,400$55.02
$4.31MSell
Eric M. DubeCEO2026-10-1537,270$54.20
$2.02MSell
Eric M. DubeCEO2026-10-15128,065$52.97
$6.78MSell
Eric M. DubeCEO2026-10-15200,000$8.93
$1.79MBuy
Peter HeermaCCO;EVP2026-09-178,282$22.40
$185.52kBuy
Eric M. DubeCEO2026-09-17101,691$64.59
$6.57MSell
Eric M. DubeCEO2026-09-17108,493$23.34
$2.53MBuy
Eric M. DubeCEO2026-09-176,802$64.95
$441.80kSell
Peter HeermaCCO;EVP2026-09-178,282$65.07
$538.92kSell

1 of 20

TVTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TVTX insiders and whales buy or sell their stock.

TVTX Shareholders

What type of owners hold Travere Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ruth Shepley51.98%49,000,000$2.47BInsider
Broadfin Healthcare Master Fund Ltd2.82%2,658,854$134.25MInsider
Opaleye GP LLC2.23%2,097,671$105.91MInsider
Martin Shkreli1.87%1,765,168$89.12MInsider
Eric M. Dube0.46%432,886$21.86MInsider
Marc L. Panoff0.23%221,100$11.16MInsider
Steve Aselage0.18%166,419$8.40MInsider
Alvin Shih0.17%158,334$7.99MInsider
Peter Heerma0.12%117,066$5.91MInsider
Elizabeth E. Reed0.11%105,389$5.32MInsider

1 of 3

TVTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TVTX0.11%61.52%Net SellingNet Selling
CRSP0.08%36.03%Net SellingNet Selling
SRRK0.11%67.31%Net Buying
ERAS0.08%24.59%Net Buying
DFTX0.09%35.38%Net SellingNet Selling

Travere Therapeutics Stock Ownership FAQ

Who owns Travere Therapeutics?

Travere Therapeutics (NASDAQ: TVTX) is owned by 0.11% institutional shareholders, 61.52% Travere Therapeutics insiders, and 38.36% retail investors. Ruth Shepley is the largest individual Travere Therapeutics shareholder, owning 49.00M shares representing 51.98% of the company. Ruth Shepley's Travere Therapeutics shares are currently valued at $2.56B.

If you're new to stock investing, here's how to buy Travere Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.